首页 | 本学科首页   官方微博 | 高级检索  
     

CD40-ATP-P2X7/NLRP3炎症信号通路在糖尿病视网膜病变中的作用研究进展
引用本文:孔慧,崔彦. CD40-ATP-P2X7/NLRP3炎症信号通路在糖尿病视网膜病变中的作用研究进展[J]. 眼科新进展, 2021, 0(9): 879-882. DOI: 10.13389/j.cnki.rao.2021.0184
作者姓名:孔慧  崔彦
作者单位:250022 山东省济南市,山东中医药大学(孔慧);250012 山东省济南市,山东大学齐鲁医院眼科(崔彦)
摘    要:糖尿病视网膜病变是糖尿病的严重并发症。炎症反应在糖尿病视网膜病变的发生发展中起着重要的作用。在高糖状态下,糖尿病患者视网膜胶质细胞以及血管内皮细胞间通过CD40-ATP-P2X7受体信号通路相互作用,诱发视网膜神经血管单元炎症级联反应,造成中低度慢性炎症及视网膜损伤。本文回顾糖尿病视网膜病变炎症机制的研究进展,对近年来CD40-ATP-P2X7/NLRP3炎症信号通路参与糖尿病视网膜病变的临床及实验研究进行综述,探讨糖尿病视网膜病变中针对该通路可能的治疗策略。

关 键 词:糖尿病视网膜病变  炎症  三磷酸腺苷  炎性小体NLRP3  视网膜神经血管单元  胶质细胞

Research progress of the CD40-ATP-P2X7/NLRP3 inflammatory pathway in diabetic retinopathy
KONG Hui1,CUI Yan2. Research progress of the CD40-ATP-P2X7/NLRP3 inflammatory pathway in diabetic retinopathy[J]. Recent Advances in Ophthalmology, 2021, 0(9): 879-882. DOI: 10.13389/j.cnki.rao.2021.0184
Authors:KONG Hui1  CUI Yan2
Affiliation:1.Shandong Traditional Chinese Medicine University,Jinan 250022,Shandong Province,China2.Deparment of Ophthalmology,Qilu Hospital of Shandong University,Jinan 250012,Shandong Province,China
Abstract:Diabetic retinopathy (DR) is a serious complication of diabetes, in which inflammation response plays an important role. In the high-glucose state, retinal glial cells interact with vascular endothelial cells in diabetic patients through the CD40-ATP-P2X7 receptor signaling pathway, thus inducing the inflammatory cascade reaction of retinal neurovascular units, and resulting in moderate to low degree chronic inflammation and retinal damage. This study retrospectively reviewed the research progress on the inflammatory mechanism of DR, and summarized latest clinical and experimental studies on the involvement of the CD40-ATP-P2X7/NLRP3 signaling pathway in DR. We also discuss the possible therapeutic strategies targeting this pathway in DR.
Keywords:diabetic retinopathy   inflammation   adenosine triphosphate   NLRP3   retinal neurovascular unit   glial cells
点击此处可从《眼科新进展》浏览原始摘要信息
点击此处可从《眼科新进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号